- Home
- Applications
- north america
- microfluidics
Show results for
Refine by
Microfluidics Product Applications In North America
6 applications found
NanoCellect Biomedical provides cell sorting solutions that allow to sort cells and establish stable cell lines using gentle low-pressure microfluidics. The WOLF’s ability to protect cell viability after sorting makes it an integral part of any cell line development workflow such as: Recombinant protein production in CHO Cells, Sorting stem cell cultures, Antibody ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)
Building on our expertise in cell sorting tools incorporating shadow imaging for detection and characterization of cells, we are developing medical diagnostic devices leveraging these technologies, along with microfluidic integrated biosensors, to capture and quantify cells from unprocessed whole blood or other body fluids. ...
ByZyMōt Fertility, Inc. based in Gaithersburg, MARYLAND (USA)
Sample preparation is a significant yet underappreciated step that allows for high quality sequencing and analysis, critical to achieving breakthroughs in medicine, agriculture, and other industries. NanoCellect’s microfluidic cell sorter, the WOLF, allow the cell’s integrity to be maintained for numerous sequencing and multi-omics techniques. ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)
Isolating edited-pluripotent stem cells with traditional sorting techniques can subject the cells to rough conditions in which gene expression, genomic stability and overall cell-health can become compromised. Microfluidic cell sorting with the WOLF, along with single cell deposition using the N1 single cell dispenser, eliminates the challenges that pluripotent stem cells face by sorting at gentle pressures without decompression shock and shear stress, and allow for efficient single cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)
Real-time Viral Titer Assay Capability. Current viral titer assay methods, a crucial component of vaccine & CGT development and production efforts, are generally slow, labor intensive, subjective, and difficult to standardize, often resulting in large errors or failures during critical production ...
ByLumaCyte, Inc. based in Charlottesville, VIRGINIA (USA)
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)